EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseOpen Access

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Josephine Harrington iD, Anthony P Carnicelli iD, Kaiyuan Hua iD, Lars Wallentin iD, Manesh R Patel iD, Stefan H Hohnloser iD, Robert P Giugliano iD, Keith A A Fox iD, Ziad Hijazi iD, Renato D Lopes iD, Sean D Pokorney iD, Hwanhee Hong und 1 weitere

Circulation · 06.06.2023 · 147 (23) · 1748-1757

DOI: 10.1161/circulationaha.122.062752 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Circulation, erschienen am 06.06.2023. Verfasst von Josephine Harrington und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, Duke University, Durham, NC (J.H., M.R.P., R.D.L., S.D.P., C.B.G.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Embolism. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction.

Methods

Using the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database (data from RE-LY [Randomized Evaluation of Long-term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), we performed an individual patient-level network meta-analysis to evaluate the safety and efficacy of DOACs versus warfarin across continuous creatinine clearance (CrCl). A multivariable Cox model including treatment-by-CrCl interaction with random effects was fitted to estimate hazard ratios for paired treatment strategies (standard-dose DOAC, lower-dose DOAC, and warfarin). Outcomes included stroke and systemic embolism (S/SE), major bleeding, intracranial hemorrhage (ICH), and death.

Results

Among 71 683 patients (mean age, 70.6±9.4 years; 37.3% female; median follow-up, 23.1 months), the mean CrCl was 75.5±30.5 mL/min. The incidence of S/SE, major bleeding, ICH, and death increased significantly with worsening kidney function. Across continuous CrCl values down to 25 mL/min, the hazard of major bleeding did not change for patients randomized to standard-dose DOACs compared with those randomized to warfarin ( P interaction =0.61). Compared with warfarin, standard-dose DOAC use resulted in a significantly lower hazard of ICH at CrCl values

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeEmbolismHumansFemaleMiddle AgedAgedAged, 80 and overMaleWarfarinFactor XaAnticoagulantsHemorrhageIntracranial HemorrhagesKidneyAdministration, OralRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

anticoagulantsatrial fibrillationkidney

Substanzen

WarfarinFactor XaAnticoagulants

Autor:innen und Institutionen

  • Department of Medicine, Division of Cardiology, Duke University, Durham, NC (J.H., M.R.P., R.D.L., S.D.P., C.B.G.).
  • Duke Clinical Research Institute, Durham, NC (J.H., K.H., M.R.P., R.D.L., S.D.P., H.H., C.B.G.).
  • Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston (A.P.C.).
  • Uppsala Clinical Research Center (L.W.), Uppsala University, Sweden.
  • Department of Medical Sciences, Cardiology (L.W., Z.H.), Uppsala University, Sweden.
  • Department of Cardiology, JW Goethe University, Frankfurt, Germany (S.H.H.).

ORCID-Profile: Josephine Harrington, Anthony P Carnicelli, Kaiyuan Hua, Lars Wallentin, Manesh R Patel, Stefan H Hohnloser, Robert P Giugliano, Keith A A Fox, Ziad Hijazi, Renato D Lopes, Sean D Pokorney, Christopher B Granger

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Harrington, J., Carnicelli, A. P., Hua, K., Wallentin, L., Patel, M. R., Hohnloser, S. H., Giugliano, R. P., Fox, K. A. A., Hijazi, Z., Lopes, R. D., Pokorney, S. D., Hong, H., & Granger, C. B. (2023). Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. Circulation, 147(23), 1748-1757. https://doi.org/10.1161/circulationaha.122.062752

Vancouver

Harrington J, Carnicelli AP, Hua K, Wallentin L, Patel MR, Hohnloser SH, et al. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. Circulation. 2023;147(23):1748-1757. doi:10.1161/circulationaha.122.062752

BibTeX
@article{Harrington2023,
  author = {Harrington, Josephine and Carnicelli, Anthony P and Hua, Kaiyuan and Wallentin, Lars and Patel, Manesh R and Hohnloser, Stefan H and Giugliano, Robert P and Fox, Keith A A and Hijazi, Ziad and Lopes, Renato D and Pokorney, Sean D and Hong, Hwanhee and Granger, Christopher B},
  title = {Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF},
  journal = {Circulation},
  year = {2023},
  volume = {147},
  number = {23},
  pages = {1748--1757},
  doi = {10.1161/circulationaha.122.062752}
}
Kostenlos starten →